A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

NCT02181413 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

656

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Autologous Stem Cell Transplant

Interventions

DRUG: Ixazomib Citrate
DRUG: Placebo

Sponsor

Takeda